Lentivirus-mediated inhibition of USP39 suppresses the growth of breast cancer cells in vitro

Oncology Reports

Volumn 30, Issue 6, 2013, Pages 2871-2877

  Wang, Haibo ^a   Ji, Xiaojun ^a   Liu, Xiangping ^a   Yao, Ruyong ^a   Chi, Jingwei ^a   Liu, Shihai ^a   Wang, Yu ^a   Cao, Weihong ^a   Zhou, Quan ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; Deubiquitinating enzyme; Lentivirus; RNA interference; USP39

Indexed keywords

DEUBIQUITINASE; SHORT HAIRPIN RNA; UBIQUITIN SPECIFIC PROTEASE 39; UNCLASSIFIED DRUG; USP39;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GENE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; COLONY FORMING CELL; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LENTIVIRINAE; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

APOPTOSIS; BREAST NEOPLASMS; CARCINOGENESIS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LENTIVIRUS; MCF-7 CELLS; MOLECULAR TARGETED THERAPY; RNA INTERFERENCE; TRANSFECTION; UBIQUITIN-SPECIFIC PROTEASES;

EID: 84892421621     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2798     Document Type: Article

References (29)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sinha D, Biswas J, Sung B, Aggarwal BB and Bishayee A: Chemopreventive and chemotherapeutic potential of curcumin in breast cancer. Curr Drug Targets 13: 1799-1819, 2012.
3. Allgayer H and Fulda S: An introduction to molecular targeted therapy of cancer. Adva Med Sci 53: 130-138, 2008.
4. Pickart CM and Eddins MJ: Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta 1695: 55-72, 2004.
5. Pickart CM and Fushman D: Polyubiquitin chains: polymeric protein signals. Curr Opin Chem Biol 8: 610-616, 2004.
6. Ohta T and Fukuda M: Ubiquitin and breast cancer. Oncogene 23: 2079-2088, 2004.
7. Wilkinson KD: Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J 11: 1245-1256, 1997.
8. Nijman SM, Luna-Vargas MP, Velds A, et al: A genomic and functional inventory of deubiquitinating enzymes. Cell 123: 773-786, 2005.
9. Reyes-Turcu FE, Ventii KH and Wilkinson KD: Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes. Annu Rev Biochem 78: 363-397, 2009.
10. Makarova OV, Makarov EM and Luhrmann R: The 65 and 110 kDa SR-related proteins of the U4/U6.U5 tri-snRNP are essential for the assembly of mature spliceosomes. EMBO J 20: 2553-2563, 2001.
11. van Leuken RJ, Luna-Vargas MP, Sixma TK, Wolthuis RM and Medema RH: Usp39 is essential for mitotic spindle checkpoint integrity and controls mRNA-levels of aurora B. Cell Cycle 7: 2710-2719, 2008.
12. Rios Y, Melmed S, Lin S and Liu NA: Zebrafish usp39 mutation leads to rb1 mRNA splicing defect and pituitary lineage expansion. PLoS Genet 7: e1001271, 2011.
13. Izquierdo M: Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Ther 12: 217-227, 2005.
14. Qin XF, An DS, Chen IS and Baltimore D: Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100: 183-188, 2003.
15. Chen X, Zhang B and Fischer JA: A specific protein substrate for a deubiquitinating enzyme: liquid facets is the substrate of Fat facets. Genes Dev 16: 289-294, 2002.
16. Sakurai M, Ayukawa K, Setsuie R, et al: Ubiquitin C-terminal hydrolase L1 regulates the morphology of neural progenitor cells and modulates their differentiation. J Cell Sci 119: 162-171, 2006.
17. Yang JM: Emerging roles of deubiquitinating enzymes in human cancer. Acta Pharmacologica Sin 28: 1325-1330, 2007.
18. Paulsson K, Békassy AN, Olofsson T, Mitelman F, Johansson B and Panagopoulos I: A novel and cytogenetically cryptic t(7;21)(p22;q22) in acute myeloid leukemia results in fusion of RUNX1 with the ubiquitin-specific protease gene USP42. Leukemia 20: 224-229, 2006.
19. Kim J, Kim WJ, Liu Z, Loda M and Freeman MR: The ubiquitin-specific protease USP2a enhances tumor progression by targeting cyclin A1 in bladder cancer. Cell Cycle 11: 1123-1130, 2012.
20. Stevenson LF, Sparks A, Allende-Vega N, Xirodimas DP, Lane DP and Saville MK: The deubiquitinating enzyme USP2a regulates the p53 pathway by targeting Mdm2. EMBO J 26: 976-986, 2007.
21. Nijman SM, Huang TT, Dirac AM, et al: The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 17: 331-339, 2005.
22. Huang TT, Nijman SM, Mirchandani KD, et al: Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol 8: 339-347, 2006.
23. Zhang D, Zaugg K, Mak TW and Elledge SJ: A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 126: 529-542, 2006.
24. Popov N, Herold S, Llamazares M, Schulein C and Eilers M: Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 6: 2327-2331, 2007.
25. Schoenfeld AR, Apgar S, Dolios G, Wang R and Aaronson SA: BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol 24: 7444-7455, 2004.
26. Li M, Chen D, Shiloh A, et al: Deubiquitination of p53 by HAUSP is an important pathway for p53 stabilization. Nature 416: 648-653, 2002.
27. Cummins JM, Rago C, Kohli M, Kinzler KW, Lengauer C and Vogelstein B: Tumour suppression: disruption of HAUSP gene stabilizes p53. Nature 428: 1 p following 486, 2004.
28. Yuan J, Luo K, Zhang L, Cheville JC and Lou Z: USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140: 384-396, 2010.
29. Lygerou Z, Christophides G and Seraphin B: A novel genetic screen for snRNP assembly factors in yeast identifies a conserved protein, Sad1p, also required for pre-mRNA splicing. Mol Cell Biol 19: 2008-2020, 1999.